Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cornerstone Therapeutics, a specialty pharmaceutical company, has announced that, pursuant to the terms of the recently completed merger between Cornerstone BioPharma Holdings and Critical Therapeutics, Craig Collard, president and CEO and a member of Cornerstone BioPharma's directors, has been appointed chairman of the board of the newly combined company, Cornerstone Therapeutics, in addition to his position as president and CEO of the combined company.
Subscribe to our email newsletter
Also, Alastair McEwan, chairman of the board of Cornerstone BioPharma, has been appointed to the board of directors of Cornerstone Therapeutics. Concurrently, Cornerstone Therapeutics also appointed three independent directors to its board: Christopher Codeanne, Michael Enright and Michael Heffernan.
Mr Collard said: “I look forward to working closely with my fellow board members to create a leading specialty pharmaceutical company. Their diverse financial management and pharmaceutical industry backgrounds will provide us with valuable insight and experience as we continue growing our business.”